ArticleCureus2025
Positive Direct Immunofluorescence in Rowell Syndrome: Further Support for a Subtype of Cutaneous Lupus Erythematosus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rowell syndrome (RS) is a rare clinical entity characterized by erythema multiforme (EM)-like lesions and lupus erythematosus (LE). Immunologic findings associated with RS include a speckled antinuclear antibody (ANA) pattern, positive rheumatoid factor (RF), and anti-Ro (SS-A)/anti-La (SS-B) antibodies. While direct immunofluorescence (DIF) positivity is a hallmark of cutaneous LE (CLE), recent diagnostic criteria for RS suggest DIF should be negative, raising debate over whether RS is a distinct disease or a CLE variant. We present the case of a 42-year-old woman with systemic lupus erythematosus (SLE) who developed a diffuse, blistering rash consistent with RS. DIF of lesional skin demonstrated immunoreactivity for IgG, complement C3, and IgM along the basement membrane zone, contradicting the proposed RS criteria. This case reinforces the argument that RS is best classified as a CLE subtype rather than a distinct disease. The patient's clinical, serologic, and histopathologic findings, including DIF positivity, support this classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.